Morgan Leonard

Morgan Leonard

Auto-generated profile, based on publicly available information

Morgan Leonard

Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in Journal of Neural Transmission
Verified
Journal Article
Open access
PDF file
SBSibylle Bechet
Sibylle Bechet
MLMorgan Leonard
Morgan Leonard
EAEsther Ademola
Esther Ademola
JFJoëlle V. Fritz
Joëlle V. Fritz
RKRejko Krüger
Rejko Krüger
Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer’s disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson’s disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson’s disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson’s disease, including early cognitive impairments. The expanding knowledge of Parkinson’s disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson’s disease.